Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
A new antibody designed to fight B-cell lymphoma shows promise in early trials, with immune-response markers predicting which patients benefit most.
GEN3009 is a first-in-class CD37-targeting antibody engineered for enhanced complement-dependent cytotoxicity through hexamerization, tested in a 46-patient phase 1 first-in-human trial in relapsed/refractory B-cell non-Hodgkin lymphoma across 18 academic centers. The study established a safe recommended phase 2 dose of 1200 mg and, crucially, demonstrated that reductions in complement activity (CH50) correlated with objective clinical responses, validating the CDC-enhancement mechanism clinically for the first time.
What the study was
- Study design
- phase_1_trial
- Population
- Adults with relapsed/refractory B-cell non-Hodgkin lymphoma
- Sample size
- 46
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
First-in-human data for a first-in-class hexamerization-potentiated biparatopic CD37 antibody in B-NHL; establishes RP2D and novel biomarker (CH50) for response; R/R B-NHL represents high unmet need; mechanistic validation of a new antibody engineering paradigm with broad implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.